Loading
Lixte Biotechnology Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by van der Baan Bastiaan Jeroen, was filed 05 Oct 2023.
Lixte Biotechnology Holdings, Inc.: what insiders have been doing
This page follows insider dealings at Lixte Biotechnology Holdings, Inc. as filed with SEC (Form 4), a company from the Health Care sector. From 24 October 2025 to 24 October 2026, the disclosure feed for Lixte Biotechnology Holdings, Inc. logged 6 filings by 6 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
For context, the typical company on the same exchange (median of 3,167 companies) published 24 filings over the same period, against 6 filings here. The full history, which starts in 2016, counts 34 purchases against no sales.
No insider has bought Lixte Biotechnology Holdings, Inc. shares on the open market in the past twelve months. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
49
Thresholds
n/a
Buy Volume
€3M
34 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.21
Analyst consensus
Income statement
RevenueUS$172.2k
EBITDA-US$6M-3485% margin
Net income-US$6M0.0% margin
Valuation
P/Book10.6x
Beta1.05
Balance sheet & cash
Market capUS$125.4M
Total debtUS$664.5k
Free Cash Flow-US$3.1M
Debt / Equity9%
Profitability & ownership
ROE-102.0%
ROA-46.0%
% insiders7.3%
% institutions4.9%
Last declaration on 17 April 2026
Declarations49 total
25,000 sharesCommon StockSEC:0001493152-26-017856:0
25,000 sharesCommon StockSEC:0001493152-26-017852:0
25,000 sharesCommon StockSEC:0001493152-26-017853:0
25,000 sharesCommon StockSEC:0001493152-26-017854:0
350,000 sharesCommon StockSEC:0001493152-26-017855:0
50,000 sharesCommon StockSEC:0001493152-26-017857:0
10,000 shares@ US$2.8034.6% of flowCommon StockSEC:0001493152-23-036422:0
Canonical exit: 1 Jan 2024 (T+90)
5,527 shares@ US$2.5121.1% of flowCommon StockSEC:0001493152-23-035712:1
Canonical exit: 1 Jan 2024 (T+90)
4,473 shares@ US$2.2919.7% of flowCommon StockSEC:0001493152-23-035712:0
Canonical exit: 31 Dec 2023 (T+90)
10,000 shares@ US$0.495.9% of flowCommon StockSEC:0001493152-23-000449:0
Canonical exit: 30 Mar 2023 (T+90)
10,000 shares@ US$4.9059.5% of flowCommon StockSEC:0001493152-23-000255:0
Canonical exit: 30 Mar 2023 (T+90)
15,000 shares@ US$0.5114.4% of flowCommon StockSEC:0001493152-22-035794:0
Canonical exit: 15 Mar 2023 (T+90)
5,000 shares@ US$0.62715.9% of flowCommon StockSEC:0001493152-22-035281:1
Canonical exit: 9 Mar 2023 (T+90)
1,112 shares@ US$0.631.3% of flowCommon StockSEC:0001493152-22-035281:2
Canonical exit: 9 Mar 2023 (T+90)
10,000 shares@ US$0.6063.2% of flowCommon StockSEC:0001493152-22-035281:0
Canonical exit: 9 Mar 2023 (T+90)
10,000 shares@ US$0.6111.7% of flowCommon StockSEC:0001493152-22-035280:0
Canonical exit: 12 Mar 2023 (T+90)
2,484 shares@ US$0.562.7% of flowCommon StockSEC:0001493152-22-033573:1
Canonical exit: 20 Feb 2023 (T+90)
1,457 shares@ US$0.568.8% of flowCommon StockSEC:0001493152-22-033573:0
Canonical exit: 19 Feb 2023 (T+90)
2,600 shares@ US$0.5852.4% of flowCommon StockSEC:0001493152-22-033261:1
Canonical exit: 19 Feb 2023 (T+90)
2,400 shares@ US$0.57100.0% of flowCommon StockSEC:0001493152-22-033261:0
Canonical exit: 19 Feb 2023 (T+90)
7,648 shares@ US$0.5678.3% of flowCommon StockSEC:0001493152-22-033084:1
Canonical exit: 16 Feb 2023 (T+90)
2,500 shares@ US$0.55992.7% of flowCommon StockSEC:0001493152-22-033084:2
Canonical exit: 16 Feb 2023 (T+90)
6,059 shares@ US$0.55936.5% of flowCommon StockSEC:0001493152-22-033084:3
Canonical exit: 16 Feb 2023 (T+90)
4,852 shares@ US$0.539828.0% of flowCommon StockSEC:0001493152-22-033084:0
Canonical exit: 15 Feb 2023 (T+90)
52,500 shares@ US$0.5354.2% of flowCommon StockSEC:0001493152-22-032564:0
Canonical exit: 12 Feb 2023 (T+90)
25 of 49 declarations
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. is a company focused on developing cancer treatments. It specializes in discovering new therapies and technologies in the biotechnology sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
